Almost two years after Biogen swooped again into the ophthalmic gene therapy field with an $800 million buyout of eye-focused Nightstar Therapeutics, it’s turning to a young player for a new program.
Investors were none too pleased with AbbVie’s planned $63 billion buyout of Allergan, which they made clear by shaving $18 billion off the acquirer’s market cap by the end of the day Tuesday. As the analysts at RBC Capital Markets in New York watched it all play out, they wondered, will there be more Big Pharma takeouts in the weeks to come, despite the negative reaction?
Gene therapy specialist uniQure is considering selling up amid interest from large pharma buyers, according to Bloomberg. The report follows the revitalization of uniQure’s hemophilia B prospect and accompanying triple-digit stock price surge.
Add up all the money biotechs raised from initial public offerings since 2015. The sum still wouldn't surpass how much value Biogen lost Thursday after revealing its most advanced drug for Alzheimer's disease wasn't likely to succeed in late-stage clinical trials.